BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter 2023 financial results and provided an operational update.

Recent Financial and Operational Highlights

  • For the three months ended March 31, 2023, revenues were $6.6 million, a 10% increase as compared to the fourth quarter of 2022.
  • The Company shipped a net total of 48 Deep TMS™ new systems during the first quarter of 2023, bringing BrainsWay’s total Deep TMS installed base to 932 total systems as of March 31, 2023, an 18% increase from the installed base at the same point in the prior year.
  • As of March 31, 2023, the Company had shipped 453 obsessive-compulsive disorder (OCD) coils as add-on helmets to certain of BrainsWay’s new and existing systems, representing OCD treatment capability on nearly 50% of its total installed base.
  • Cash, cash equivalents, and short-term deposits as of March 31, 2023, amounted to $44.3 million, compared to $47.9 million as of December 31, 2022.
  • Recently published compelling data in Psychiatry Research demonstrating high response and remission rates for depression and anxious depression patients undergoing Deep TMS™ treatment.
    • Data from the expansive post-marketing study demonstrated that patients who had received 30 or more treatments achieved an 82% response rate and a 65% remission rate in depression symptoms. Outcomes data from 1,351 patients evaluated in the study showed that average sustained response was achieved at 16 sessions, or 21 days after beginning treatment with Deep TMS.
  • Continued to achieve reimbursement progress, increasing access for patients to the Deep TMS system.
    • BlueCross BlueShield of Mississippi issued a healthcare policy update that allows TMS trained healthcare professionals to order and provide TMS treatment to their patients with major depressive disorder (MDD).
    • United HealthCare has updated their Medicare Advantage policy in states covered by National Government Services Medicare to allow non-physician practitioners, like nurse practitioners, to order and administer TMS Therapy to their patients with MDD in states where they have scope of practice to do so.

“We remain focused on implementing key initiatives aimed at growing the Company’s top-line while simultaneously advancing toward profitability,” said Hadar Levy, BrainsWay’s Chief Executive Officer. “Importantly, we are gaining strong interest from our international business which increased significantly during the first quarter and helped facilitate our shipment of a net total of 48 systems during the quarter.”

“We also executed a number of cost optimization measures late in the first quarter that we expect to begin seeing the benefits of in the second quarter, and more meaningfully in the second half of this year,” continued Mr. Levy. “We continue to target breakeven operating income in the fourth quarter of 2023, while demonstrating full-year revenue growth over 2022.”

First Quarter 2023 Financial Results

  • Total revenues for the first quarter of 2023 were $6.6 million, compared to $8.0 million in the first quarter of 2022, a decrease of 17%.
  • Gross margin for the first quarter of 2023 was 73%, compared to 77% for the first quarter 2022.
  • Operating expenses for the first quarter of 2023 totaled $8.5 million, compared to $7.6 million for the first quarter of 2022.
  • Operating loss for the first quarter of 2023 was $3.7 million, compared to a loss of $1.5 million for the same period in 2022.
  • Net loss for the first quarter of 2023 was $2.4 million, compared to a loss of $2.0 million for the same period in 2022.

Conference Call and Webcast

BrainsWay’s management will host a conference call on Wednesday, May 17, 2023, at 8:30 a.m. Eastern Time to discuss these results and answer questions.

Wednesday, May 17, 2023, at 8:30 AM Eastern Time:

United States: 1-877-407-3982
International: 1-201-493-6780
Israel: 1-809-406-247
Conference ID: 13738617
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1613817&tp_key=17843474e5

To listen to a live webcast, please visit the Investors section of the BrainsWay website at www.BrainsWay.com. Please access the Company’s website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” “aiming,” “targeting” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Scott Areglado
SVP and Chief Financial Officer

Brian Ritchie
LifeSci Advisors

U.S. dollars in thousands
  March 31,   December 31,
    2023       2022  
ASSETS (Unaudited)
Current Assets      
Cash and cash equivalents $ 44,051     $ 47,581  
Short-term deposits   271       271  
Trade receivables, net   5,350       4,844  
Inventory   4,736       3,837  
Other current assets   1,738       1,556  
    56,146       58,089  
Non-Current Assets      
System components   483       1,220  
Leased systems, net   3,315       3,118  
Other property and equipment   947       1,008  
Other long-term assets   1,064       1,042  
    5,809     6,388  
  $ 61,955     $ 64,477  
Current Liabilities      
Trade payables $ 584     $ 1,116  
Deferred revenues   2,263       1,477  
Liability in respect of research and development grants   1,158       1,057  
Other accounts payable   5,159       4,491  
    9,164       8,141  
Non-Current Liabilities      
Deferred revenues and other liabilities   4,766       4,923  
Liability in respect of research and development grants   5,108       6,016  
    9,874       10,939  
Share capital   364       364  
Share premium   138,146       138,146  
Share-based payment reserve   6,132       6,180  
Currency Translation Adjustments   (2,188 )     (2,188 )
Accumulated deficit   (99,537 )     (97,105 )
    42,917       45,397  
  $ 61,955     $ 64,477  

U.S. dollars in thousands (except per share data)
  For the three months ended March 31,
    2023       2022  
Revenues $ 6,625     $ 7,970  
Cost of revenues   1,792       1,867  
Gross profit   4,833       6,103  
Selling and marketing expenses   4,912       4,146  
Research and development expenses, net   1,785       1,576  
General and administrative expenses   1,803       1,863  
Total operating expenses   8,500       7,585  
Operating loss   (3,667 )     (1,482 )
Finance income (expense), net   1,407       (324 )
Loss before income taxes   (2,260 )     (1,806 )
Taxes on income   171       187  
Net loss and total comprehensive loss $ (2,431 )   $ (1,993 )
Basic and diluted net loss per share $ (0.07 )   $ (0.05 )

U.S. dollars in thousands
  For the three months ended March 31,
    2023       2022  
Cash flows from operating activities:      
Total comprehensive loss $ (2,431 )   $ (1,993 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Adjustments to profit or loss items:      
Depreciation and amortization   93       142  
Depreciation of leased systems   233       245  
Impairments and disposals   246       (68 )
Finance expenses, net   (1,471 )     324  
Cost of share based payment   (51 )     374  
Income taxes   171       187  
Total adjustments to reconcile loss   (779 )     1,204  
Changes in asset and liability items:      
Increase in trade receivables   (493 )     (63 )
Increase in inventory   (928 )     (1,313 )
Increase in other accounts receivable   (222 )     (61 )
Decrease in trade payables   (535 )     (512 )
Increase (decrease) in other accounts payable   511       (510 )
Increase in deferred revenues and other liabilities   700       273  
Total changes in asset and liability   (967 )     (2,186 )
Cash paid and received during the period for:      
Interest paid   (31 )     (12 )
Interest received   674       3  
Income taxes paid   (7 )     (3 )
Total cash paid and received during the period   636       (12 )
Net cash provided by (used in) operating activities:   (3,541 )     (2,987 )
Cash flows from investing activities:      
Proceeds from property and equipment and system components, net   66       951  
Withdrawal of (investment in) short-term deposits, net         (50 )
Investment in long-term deposits, net   (2 )     (3 )
Net cash provided by (used in) investing activities   64       898  
Cash flows from financing activities:      
Repayment of liability in respect of research and development grants         (498 )
Receipt of government grants         6  
Repayment of lease liability   (66 )     (148 )
Issuance of share capital, net         1  
Net cash used in financing activities   (66 )     (639 )
Exchange rate differences on cash and cash equivalents   13       (88 )
Decrease in cash and cash equivalents   (3,530 )     (2,816 )
Cash and cash equivalents at the beginning of the period   47,581       16,921  
Cash and cash equivalents at the end of the period $ 44,051     $ 14,105  
(a) Significant non cash transactions:      
Recognition of new lease liability and right-of-use   24        
Termination of lease liability and right-of-use   11        

error: Content is protected !!